Unravelling the etiology of sporadic late-onset cerebellar ataxia in a cohort of 205 patients: a prospective study.


Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 14 02 2022
accepted: 23 06 2022
revised: 22 06 2022
pubmed: 24 7 2022
medline: 2 11 2022
entrez: 23 7 2022
Statut: ppublish

Résumé

Despite recent progress in the field of genetics, sporadic late-onset (> 40 years) cerebellar ataxia (SLOCA) etiology remains frequently elusive, while the optimal diagnostic workup still needs to be determined. We aimed to comprehensively describe the causes of SLOCA and to discuss the relevance of the investigations. We included 205 consecutive patients with SLOCA seen in our referral center. Patients were prospectively investigated using exhaustive clinical assessment, biochemical, genetic, electrophysiological, and imaging explorations. We established a diagnosis in 135 (66%) patients and reported 26 different causes for SLOCA, the most frequent being multiple system atrophy cerebellar type (MSA-C) (41%). Fifty-one patients (25%) had various causes of SLOCA including immune-mediated diseases such as multiple sclerosis or anti-GAD antibody-mediated ataxia; and other causes, such as alcoholic cerebellar degeneration, superficial siderosis, or Creutzfeldt-Jakob disease. We also identified 11 genetic causes in 20 patients, including SPG7 (n = 4), RFC1-associated CANVAS (n = 3), SLC20A2 (n = 3), very-late-onset Friedreich's ataxia (n = 2), FXTAS (n = 2), SCA3 (n = 1), SCA17 (n = 1), DRPLA (n = 1), MYORG (n = 1), MELAS (n = 1), and a mitochondriopathy (n = 1) that were less severe than MSA-C (p < 0.001). Remaining patients (34%) had idiopathic late-onset cerebellar ataxia which was less severe than MSA-C (p < 0.01). Our prospective study provides an exhaustive picture of the etiology of SLOCA and clues regarding yield of investigations and diagnostic workup. Based on our observations, we established a diagnostic algorithm for SLOCA.

Sections du résumé

BACKGROUND BACKGROUND
Despite recent progress in the field of genetics, sporadic late-onset (> 40 years) cerebellar ataxia (SLOCA) etiology remains frequently elusive, while the optimal diagnostic workup still needs to be determined. We aimed to comprehensively describe the causes of SLOCA and to discuss the relevance of the investigations.
METHODS METHODS
We included 205 consecutive patients with SLOCA seen in our referral center. Patients were prospectively investigated using exhaustive clinical assessment, biochemical, genetic, electrophysiological, and imaging explorations.
RESULTS RESULTS
We established a diagnosis in 135 (66%) patients and reported 26 different causes for SLOCA, the most frequent being multiple system atrophy cerebellar type (MSA-C) (41%). Fifty-one patients (25%) had various causes of SLOCA including immune-mediated diseases such as multiple sclerosis or anti-GAD antibody-mediated ataxia; and other causes, such as alcoholic cerebellar degeneration, superficial siderosis, or Creutzfeldt-Jakob disease. We also identified 11 genetic causes in 20 patients, including SPG7 (n = 4), RFC1-associated CANVAS (n = 3), SLC20A2 (n = 3), very-late-onset Friedreich's ataxia (n = 2), FXTAS (n = 2), SCA3 (n = 1), SCA17 (n = 1), DRPLA (n = 1), MYORG (n = 1), MELAS (n = 1), and a mitochondriopathy (n = 1) that were less severe than MSA-C (p < 0.001). Remaining patients (34%) had idiopathic late-onset cerebellar ataxia which was less severe than MSA-C (p < 0.01).
CONCLUSION CONCLUSIONS
Our prospective study provides an exhaustive picture of the etiology of SLOCA and clues regarding yield of investigations and diagnostic workup. Based on our observations, we established a diagnostic algorithm for SLOCA.

Identifiants

pubmed: 35869996
doi: 10.1007/s00415-022-11253-1
pii: 10.1007/s00415-022-11253-1
doi:

Substances chimiques

SLC20A2 protein, human 0
Sodium-Phosphate Cotransporter Proteins, Type III 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6354-6365

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Références

Mahlknecht P, Kiechl S, Bloem BR et al (2013) Prevalence and burden of gait disorders in elderly men and women aged 60–97 years: a population-based study. PLoS ONE 8:e69627. https://doi.org/10.1371/journal.pone.0069627
doi: 10.1371/journal.pone.0069627 pubmed: 23894511 pmcid: 3722115
Muzaimi MB (2004) Population based study of late onset cerebellar ataxia in south east Wales. J Neurol Neurosurg Psychiatry 75:1129–1134. https://doi.org/10.1136/jnnp.2003.014662
doi: 10.1136/jnnp.2003.014662 pubmed: 15258214 pmcid: 1739172
Klockgether T (2010) Sporadic ataxia with adult onset: classification and diagnostic criteria. Lancet Neurol 9:94–104. https://doi.org/10.1016/S1474-4422(09)70305-9
doi: 10.1016/S1474-4422(09)70305-9 pubmed: 20083040
Cortese A, Simone R, Sullivan R et al (2019) Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia. Nat Genet 51:649–658. https://doi.org/10.1038/s41588-019-0372-4
doi: 10.1038/s41588-019-0372-4 pubmed: 30926972 pmcid: 6709527
Pfeffer G, Pyle A, Griffin H et al (2015) SPG7 mutations are a common cause of undiagnosed ataxia. Neurology 84:1174–1176. https://doi.org/10.1212/WNL.0000000000001369
doi: 10.1212/WNL.0000000000001369 pubmed: 25681447 pmcid: 4371411
Manto M, Gandini J, Feil K, Strupp M (2020) Cerebellar ataxias: an update. Curr Opin Neurol 33:150–160. https://doi.org/10.1097/WCO.0000000000000774
doi: 10.1097/WCO.0000000000000774 pubmed: 31789706
Lieto M, Roca A, Santorelli FM et al (2019) Degenerative and acquired sporadic adult onset ataxia. Neurol Sci 40:1335–1342. https://doi.org/10.1007/s10072-019-03856-w
doi: 10.1007/s10072-019-03856-w pubmed: 30927137
Schmitz-Hubsch T, du Montcel ST, Baliko L et al (2006) Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66:1717–1720. https://doi.org/10.1212/01.wnl.0000219042.60538.92
doi: 10.1212/01.wnl.0000219042.60538.92 pubmed: 16769946
Goetz CG, Tilley BC, Shaftman SR et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results: MDS-UPDRS: Clinimetric Assessment. Mov Disord 23:2129–2170. https://doi.org/10.1002/mds.22340
doi: 10.1002/mds.22340 pubmed: 19025984
Anheim M, Fleury M, Monga B et al (2010) Epidemiological, clinical, paraclinical and molecular study of a cohort of 102 patients affected with autosomal recessive progressive cerebellar ataxia from Alsace, Eastern France: implications for clinical management. Neurogenetics 11:1–12. https://doi.org/10.1007/s10048-009-0196-y
doi: 10.1007/s10048-009-0196-y pubmed: 19440741
Bonnard C, Wirth T, Gebus O et al (2020) Clonidine GH stimulation test to differentiate MSA from idiopathic late onset cerebellar ataxia: a prospective, controlled study. J Neurol 267:855–859. https://doi.org/10.1007/s00415-020-09737-z
doi: 10.1007/s00415-020-09737-z pubmed: 32034477
Carré G, Dietemann JL, Gebus O et al (2020) Brain MRI of multiple system atrophy of cerebellar type: a prospective study with implications for diagnosis criteria. J Neurol 267:1269–1277. https://doi.org/10.1007/s00415-020-09702-w
doi: 10.1007/s00415-020-09702-w pubmed: 31938861
Anheim M, Lagier-Tourenne C, Stevanin G et al (2009) SPG11 spastic paraplegia: a new cause of juvenile parkinsonism. J Neurol 256:104–108. https://doi.org/10.1007/s00415-009-0083-3
doi: 10.1007/s00415-009-0083-3 pubmed: 19224311
Montaut S, Diedhiou N, Fahrer P et al (2021) Biallelic RFC1-expansion in a French multicentric sporadic ataxia cohort. J Neurol 268:3337–3343. https://doi.org/10.1007/s00415-021-10499-5
doi: 10.1007/s00415-021-10499-5 pubmed: 33666721
Gebus O, Montaut S, Monga B et al (2017) Deciphering the causes of sporadic late-onset cerebellar ataxias: a prospective study with implications for diagnostic work. J Neurol 264:1118–1126. https://doi.org/10.1007/s00415-017-8500-5
doi: 10.1007/s00415-017-8500-5 pubmed: 28478596
Gilman S, Wenning GK, Low PA et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71:670–676. https://doi.org/10.1212/01.wnl.0000324625.00404.15
doi: 10.1212/01.wnl.0000324625.00404.15 pubmed: 18725592 pmcid: 2676993
Höglinger GU, Respondek G, Stamelou M et al (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria: MDS Clinical Diagnostic Criteria for PSP. Mov Disord 32:853–864. https://doi.org/10.1002/mds.26987
doi: 10.1002/mds.26987 pubmed: 28467028 pmcid: 5516529
Vitali C (2002) Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558. https://doi.org/10.1136/ard.61.6.554
doi: 10.1136/ard.61.6.554 pubmed: 12006334 pmcid: 1754137
Giordano I, Harmuth F, Jacobi H et al (2017) Clinical and genetic characteristics of sporadic adult-onset degenerative ataxia. Neurology 89:1043–1049. https://doi.org/10.1212/WNL.0000000000004311
doi: 10.1212/WNL.0000000000004311 pubmed: 28794257
Hewamadduma CA, Hoggard N, O’Malley R et al (2018) Novel genotype-phenotype and MRI correlations in a large cohort of patients with SPG7 mutations. Neurol Genet 4:e279. https://doi.org/10.1212/NXG.0000000000000279
doi: 10.1212/NXG.0000000000000279 pubmed: 30533525 pmcid: 6244025
De la Casa-Fages B, Fernández-Eulate G, Gamez J et al (2019) Parkinsonism and spastic paraplegia type 7: expanding the spectrum of mitochondrial Parkinsonism. Mov Disord 34:1547–1561. https://doi.org/10.1002/mds.27812
doi: 10.1002/mds.27812 pubmed: 31433872
Aboud Syriani D, Wong D, Andani S et al (2020) Prevalence of RFC1 -mediated spinocerebellar ataxia in a North American ataxia cohort. Neurol Genet 6:e440. https://doi.org/10.1212/NXG.0000000000000440
doi: 10.1212/NXG.0000000000000440 pubmed: 32582864 pmcid: 7274910
Traschütz A, Cortese A, Reich S et al (2021) Natural History, phenotypic spectrum, and discriminative features of multisystemic RFC1 disease. Neurology 96:e1369–e1382. https://doi.org/10.1212/WNL.0000000000011528
doi: 10.1212/WNL.0000000000011528 pubmed: 33495376 pmcid: 8055326
Matos PCAAP, Rezende TJR, Schmitt GS, et al (2021) Brain structural signature of RFC1‐related disorder. Mov Disord. https://doi.org/10.1002/mds.28711
Silva Schmitt G, Martinez ARM, Graça FF et al (2020) Dopa-responsive parkinsonism in a patient with homozygous RFC1 expansions. Mov Disord 35:1889–1890. https://doi.org/10.1002/mds.28286
doi: 10.1002/mds.28286 pubmed: 33068476
Wan L, Chen Z, Wan N et al (2020) Biallelic intronic AAGGG expansion of RFC1 is related to multiple system atrophy. Ann Neurol 88:1132–1143. https://doi.org/10.1002/ana.25902
doi: 10.1002/ana.25902 pubmed: 32939785
Sullivan R, Yau WY, Chelban V et al (2020) RFC1 intronic repeat expansions absent in pathologically confirmed multiple systems atrophy. Mov Disord 35:1277–1279. https://doi.org/10.1002/mds.28074
doi: 10.1002/mds.28074 pubmed: 32333430
Hadjivassiliou M, Graus F, Honnorat J et al (2020) Diagnostic criteria for primary autoimmune cerebellar ataxia—guidelines from an international task force on immune-mediated cerebellar ataxias. Cerebellum 19:605–610. https://doi.org/10.1007/s12311-020-01132-8
doi: 10.1007/s12311-020-01132-8 pubmed: 32328884 pmcid: 7351847

Auteurs

T Bogdan (T)

Neurology Department, Strasbourg University Hospital, Strasbourg, France. thomas.bogdan@chru-strasbourg.fr.

T Wirth (T)

Neurology Department, Strasbourg University Hospital, Strasbourg, France.
Strasbourg Federation of Translational Medicine (FMTS), Strasbourg University, Strasbourg, France.
INSERM-U964; CNRS-UMR7104, University of Strasbourg, Illkirch-Graffenstaden, France.

A Iosif (A)

Neurology Department, Strasbourg University Hospital, Strasbourg, France.

A Schalk (A)

Strasbourg Federation of Translational Medicine (FMTS), Strasbourg University, Strasbourg, France.
Laboratory of Genetic Diagnosis, IGMA, Strasbourg University Hospital, Strasbourg, France.

S Montaut (S)

Neurology Department, Strasbourg University Hospital, Strasbourg, France.

C Bonnard (C)

Neurology Department, Strasbourg University Hospital, Strasbourg, France.

G Carre (G)

Neurology Department, Strasbourg University Hospital, Strasbourg, France.

O Lagha-Boukbiza (O)

Neurology Department, Strasbourg University Hospital, Strasbourg, France.

C Reschwein (C)

Neurology Department, Strasbourg University Hospital, Strasbourg, France.

E Albugues (E)

Neurology Department, Strasbourg University Hospital, Strasbourg, France.

S Demuth (S)

Neurology Department, Strasbourg University Hospital, Strasbourg, France.

H Landsberger (H)

Neurology Department, Strasbourg University Hospital, Strasbourg, France.

M Einsiedler (M)

Neurology Department, Strasbourg University Hospital, Strasbourg, France.

T Parratte (T)

Neurology Department, Strasbourg University Hospital, Strasbourg, France.

A Nguyen (A)

Neurology Department, Strasbourg University Hospital, Strasbourg, France.

F Lamy (F)

Neurology Department, Strasbourg University Hospital, Strasbourg, France.

H Durand (H)

Neurology Department, Strasbourg University Hospital, Strasbourg, France.

P Fahrer (P)

Neurology Department, Strasbourg University Hospital, Strasbourg, France.

P Voulleminot (P)

Neurology Department, Strasbourg University Hospital, Strasbourg, France.

K Bigaut (K)

Neurology Department, Strasbourg University Hospital, Strasbourg, France.

J B Chanson (JB)

Neurology Department, Strasbourg University Hospital, Strasbourg, France.

G Nicolas (G)

Department of Genetics and CNRMAJ, FHU G4 Génomique, Normandie Univ, UNIROUEN, Inserm U1245 and CHU Rouen, 76000, Rouen, France.

J Chelly (J)

Laboratory of Genetic Diagnosis, IGMA, Strasbourg University Hospital, Strasbourg, France.

C Cazeneuve (C)

Neurogenetics Laboratory, Department of Genetics, APHP, University Hospital Pitié-Salpêtrière, Paris, France.

M Koenig (M)

Laboratory of Molecular Genetics, Montpellier University Hospital, Montpellier, France.

C Bund (C)

Department of Nuclear Medicine, Strasbourg University Hospital, Strasbourg, France.
Department of Nuclear Medicine and Molecular Imaging, ICANS, Strasbourg, France.

I J Namer (IJ)

Department of Nuclear Medicine, Strasbourg University Hospital, Strasbourg, France.
Department of Nuclear Medicine and Molecular Imaging, ICANS, Strasbourg, France.

S Kremer (S)

Department of Radiology, Strasbourg University Hospital, Strasbourg, France.

N Calmels (N)

Laboratory of Genetic Diagnosis, IGMA, Strasbourg University Hospital, Strasbourg, France.

C Tranchant (C)

Neurology Department, Strasbourg University Hospital, Strasbourg, France.
Strasbourg Federation of Translational Medicine (FMTS), Strasbourg University, Strasbourg, France.
INSERM-U964; CNRS-UMR7104, University of Strasbourg, Illkirch-Graffenstaden, France.

M Anheim (M)

Neurology Department, Strasbourg University Hospital, Strasbourg, France.
Strasbourg Federation of Translational Medicine (FMTS), Strasbourg University, Strasbourg, France.
INSERM-U964; CNRS-UMR7104, University of Strasbourg, Illkirch-Graffenstaden, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH